The Muscular Dystrophy drugs in development market research report provides comprehensive information on the therapeutics under development for Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Muscular Dystrophy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued products.
GlobalData tracks 133 drugs in development for Muscular Dystrophy by 101 companies/universities/institutes. The top development phase for Muscular Dystrophy is preclinical with 56 drugs in that stage. The Muscular Dystrophy pipeline has 116 drugs in development by companies and 17 by universities/ institutes. Some of the companies in the Muscular Dystrophy pipeline products market are: Sarepta Therapeutics, Kate Therapeutics and Sanofi.
The key targets in the Muscular Dystrophy pipeline products market include Myotonin Protein Kinase, Double Homeobox Protein 4, and Dysferlin.
The key mechanisms of action in the Muscular Dystrophy pipeline product include Double Homeobox Protein 4 Inhibitor with 16 drugs in Phase II. The Muscular Dystrophy pipeline products include eight routes of administration with the top ROA being Intravenous and 15 key molecule types in the Muscular Dystrophy pipeline products market including Small Molecule, and Gene Therapy.
Muscular Dystrophy overview
Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking.
For a complete picture of Muscular Dystrophy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
